BIAF bioAffinity Technologies, Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BIAF
—
—
What changed
Recent filings, trades and moves- Nov 6 8-K: Earnings results
- Nov 6 Quarterly report (10-Q) filed
Key stats
Related
About
- Industry (SIC)
- SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH (8731) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 57
- List Date
- 2022-09-01
- CIK
- 0001712762
- Last Earnings
- Aug 7
- Next Earnings
- ~Nov 13, 2026 (estimated)
- Headquarters
- San Antonio, TX
- Homepage
- https://www.bioaffinitytech.com
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma a…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 67.31% | -7.10% | -19.17% | -6.56% | 8.62% |
| Feb | -- | -34.62% | 50.65% | -29.60% | -16.54% | -7.53% |
| Mar | -- | 13.86% | -3.81% | -36.59% | 261.32% | 58.70% |
| Apr | -- | 18.90% | 17.22% | -56.88% | -37.56% | -14.58% |
| May | -- | -10.73% | -2.04% | -41.05% | -23.74% | -19.39% |
| Jun | -- | 0.55% | -8.86% | 9.33% | -53.60% | -13.14% |
| Jul | -- | -6.88% | 12.16% | 20.30% | -25.62% | -0.01% |
| Aug | -- | -6.99% | -36.97% | -17.54% | -49.11% | -27.65% |
| Sep | -64.94% | -35.34% | 49.64% | -58.32% | -0.46% | -21.88% |
| Oct | 13.55% | -11.15% | -30.58% | -15.52% | -52.64% | -19.27% |
| Nov | -3.57% | 29.69% | -11.31% | -34.78% | -20.07%* | -8.01% |
| Dec | -42.24% | -12.99% | -19.47% | -13.87% | -- | -22.14% |
| Total | -77.83% | -25.36% | -26.10% | -98.03% | -91.12% | -63.69% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.04
SMA 50: $5.72
SMA 200: $18.55
Current: $2.39
EMA 12: $2.80
EMA 26: $3.61
MACD: -0.8111 | Signal: 0.0816
BEARISH
ADX (14): 9.93
RANGE
+DI: 24.96
−DI: 30.78
Momentum Oscillators
RSI (14): 33.49
NEUTRAL
Stoch %K: 7.86
Stoch %D: 7.56
Williams %R: -86.55
Volume & Volatility
BB Upper: $3.95
BB Lower: $2.13
NEUTRAL
OBV: 185,383,004
Vol SMA 20: 102,508
Vol ROC: -81.13%
ATR: $0.54
True Range: $0.03
HV 20: 124.1%
HV 30: 124.2%
HV 60: 242.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
LLM Stock Analysis Report: BIAF
Executive Summary
Overall Assessment: BEARISH (confidence level 7/10)
Key Drivers:
- Bearish MACD signal
- Strong ADX indicating a robust downtrend
- High volatility, suggesting increased risk
Primary Risks:
- Momentum indicators align with the bearish trend
- Resistance levels above $12.40 could trigger significant selling pressure
Investment Thesis: BIAF's technical signals and recent news sentiment suggest a high-risk trading environment. The stock's strong downtrend and high volatility increase the likelihood of further price declines.
Recent News Sentiment Impact: The positive news headlines have had little impact on the stock, as the bearish trend has persisted despite the neutral to positive sentiment.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Downtrend
- Medium-term (1-3 months): Downtrend
- Long-term (3-12 months): Neutral
Support/Resistance Levels:
- Key price levels:
- SMA 20: $7.06 (support)
- Upper Bollinger Band: $12.40 (resistance)
Momentum Signals:
- RSI interpretation: Oversold (<30), but recent upward momentum has pushed the RSI into neutral territory.
- MACD signal: Bearish
- Bollinger Bands position: Squeeze, indicating potential mean reversion
Volume Analysis:
- Volume trends: Increasing volume on price declines suggests institutional selling pressure.
- Institutional interest signals: High IV rank and put/call ratios indicate increased risk.
News & Sentiment Analysis
Recent Headlines Summary:
- 5 neutral news headlines with no significant impact on the stock
- 1 positive headline (12 Health Care Stocks Moving In Friday's Pre-Market Session) had little effect on the stock's price
Sentiment Assessment: Neutral to slightly positive sentiment overall.
Catalyst Identification:
- No imminent catalysts, but potential support at SMA 20 ($7.06)
Market Narrative:
- Technical signals and recent news sentiment align with a bearish narrative, while Bollinger Bands indicate potential mean reversion.
Risk & Volatility Assessment
Risk Assessment: High (beta >1.5, high volatility, negative news sentiment)
Volatility Regime: High (2.13), indicating increased risk.
Options Market Signals:
- IV rank: 85.67
- Put/call ratios: 0.63 (neutral to bearish)
- Unusual activity: N/A
Downside Protection:
- Support levels: SMA 20 ($7.06) and Lower Bollinger Band ($1.72)
Market Context & Positioning
Sector Performance: Neutral to slightly positive (health care sector performance).
Institutional Activity: High institutional selling pressure, indicated by increasing volume on price declines.
Correlation Analysis:
- R-squared interpretation: 0.14 indicates a weak correlation with the market.
Relative Valuation: Neutral to bearish, considering the stock's high volatility and recent price declines.
Key Levels & Action Items
Critical Price Levels:
- SMA 20 ($7.06): support
- Upper Bollinger Band ($12.40): resistance
Breakout/Breakdown Levels:
- SMA 50: $9.01 (breakout/breakdown potential)
Time-Sensitive Catalysts:
- No imminent catalysts, but potential support at SMA 20 ($7.06) if the stock reaches this level.
Risk Management:
- Stop-loss levels: below SMA 20 ($7.06)
- Position sizing considerations: avoid large positions due to high volatility and risk.
This report provides a comprehensive analysis of BIAF's technical signals, news sentiment, and market context. The bearish trend, strong downtrend, and high volatility suggest a high-risk trading environment. Investors should exercise caution and consider the potential risks before making any investment decisions.
Generated
News
All BIAF news →
BIAF Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 2.1332
Alpha: -98.14%
Correlation: 0.1398
R-Squared: 2.0%
Stock Volatility: 208.6%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
BIAF Institutional Ownership (13F)
Filings for 2026-06-30 · 3 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
BIAF Board & Officers
As of SEC filings through Sep 25, 2025The company's insiders have not filed since Sep 25, 2025; this reflects that date.
Directors 8
- Maria Zannes · since Aug 29, 2022
- Peter S Knight · since Aug 29, 2022
- Robert A. Anderson · since Aug 29, 2022
- Steven Girgenti · since Aug 29, 2022
- Roby Joyce · since Sep 18, 2023
- Jamie Platt · since Dec 1, 2023
- John J. Oppenheimer · since Aug 12, 2025
- Roberto Rios · since Aug 12, 2025
Officers 6
- Maria Zannes · President, CEO · since Aug 29, 2022
- James Michael Edwards · VP and CFO · listed since Nov 2024
- Xavier Trinidad Reveles · Chief Operating Officer · since Sep 18, 2023
- Vivienne I Rebel · EVP, Chief Sci. & Med. Officer · since Aug 29, 2022
- Timothy P Zannes · Secretary, EVP, Gen. Counsel · since Aug 29, 2022
- Steven Girgenti · Executive Chairman · since Aug 29, 2022
10% owners 2
- Gary D Rubin · since Aug 29, 2022
- Harvey Sandler Revocable Trust (entity) · since Aug 29, 2022
Changes in the last 10 years (27)
| Aug 12, 2025 | The company announced the departure of Gary D Rubin from the board in an SEC filing |
| Aug 12, 2025 | Roberto Rios became a director |
| Aug 12, 2025 | John J. Oppenheimer became a director |
| Apr 12, 2025 | The company announced the departure of Stuart Diamond from the board in an SEC filing |
| Nov 5, 2024 | James Michael Edwards listed as VP and CFO (previously Chief Financial Officer) in SEC filings |
| Aug 19, 2024 | The company announced the departure of Michael Philip Dougherty as Chief Financial Officer in an SEC filing |
| Jan 24, 2024 | Mohsin Y Meghji reported in an SEC filing no longer being a director |
| Dec 1, 2023 | Jamie Platt became a director |
| Sep 18, 2023 | Xavier Trinidad Reveles became Chief Operating Officer |
| Sep 18, 2023 | Roby Joyce became a director |
| May 1, 2023 | Michael Philip Dougherty became Chief Financial Officer |
| Mar 7, 2023 | Nathan M Perlmutter reported in an SEC filing no longer being a 10% owner |
| Aug 29, 2022 | Vivienne I Rebel became EVP, Chief Sci. & Med. Officer |
| Aug 29, 2022 | Timothy P Zannes became Secretary, EVP, Gen. Counsel |
| Aug 29, 2022 | Stuart Diamond became a director |
| Aug 29, 2022 | Steven Girgenti became a director |
| Aug 29, 2022 | Steven Girgenti became Executive Chairman |
| Aug 29, 2022 | Robert A. Anderson became a director |
| Aug 29, 2022 | Peter S Knight became a director |
| Aug 29, 2022 | Nathan M Perlmutter became a 10% owner |
| Aug 29, 2022 | Mohsin Y Meghji became a director |
| Aug 29, 2022 | Maria Zannes became a director |
| Aug 29, 2022 | Maria Zannes became President, CEO |
| Aug 29, 2022 | James Michael Edwards became Chief Financial Officer |
| Aug 29, 2022 | Harvey Sandler Revocable Trust became a 10% owner |
| Aug 29, 2022 | Gary D Rubin became a director |
| Aug 29, 2022 | Gary D Rubin became a 10% owner |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-06
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-06 | Earnings results | EDGAR |
| 2026-10-29 | Other events | EDGAR |
| 2026-10-15 | Other events | EDGAR |
| 2026-10-13 | Other events | EDGAR |
| 2026-10-09 | Material agreement · Unregistered share sale · Other events | EDGAR |
| 2026-10-08 | Other events | EDGAR |
| 2026-10-06 | Other events | EDGAR |
| 2026-09-30 | Other events | EDGAR |
| 2026-09-22 | Other events | EDGAR |
| 2026-09-17 | Other events | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
1 ETF hold BIAF
1 shown · $24.28K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $24,279 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
BIAF vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| IQV IQVIA Holdings Inc. | $46.0B | 33.8 | +8.8% | +23.4% | 31 |
| INCY Incyte Genomics Inc | $24.8B | 64.1 | +24.9% | +18.8% | 68 |
| MEDP Medpace Holdings, Inc. Common Stock | $18.8B | 36.9 | +20.4% | +16.7% | 9 |
| CRL Charles River Laboratories International | $16.9B | 410.6 | −1.2% | +72.4% | 34 |
| ICLR Icon Plc | $15.6B | — | — | +7.7% | 28 |
| ABSI Absci Corporation Common Stock | $1.9B | — | −62.3% | +174.5% | 82 |
| OABI OmniAb, Inc. Common Stock | $773M | — | +67.0% | +169.7% | 22 |
| NRC NRC Health Common Stock | $566M | 99.6 | +3.4% | +49.2% | 7 |
| BIAF bioAffinity Technologies, Inc. Common St | $1M | — | — | −86.9% | — |
| Peer median | $16.2B | 64.1 | +8.8% | +36.3% | 29 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.